All aquisitions in recent years (eg Arrow Generics & BMS Products and Manufacturing) are strategies to provide new products and capacity.........for significant future growth! There is still potential for rationalisation in the wholesaling and generics area which could be positive for Sigma.
CSL are in a different ball park (Vaccines and blood products........highly specialised.....unique and global). Those who took up shares in the original float have certainly had spectacular capital growth to say the least. One that got away for me!
Add to My Watchlist
What is My Watchlist?